Prophylaxis for COVID-19: a systematic review - PubMed (original) (raw)

Prophylaxis for COVID-19: a systematic review

Mikaela Smit et al. Clin Microbiol Infect. 2021 Apr.

Abstract

Background: While the landscape of vaccine and treatment candidates against the novel coronavirus disease 2019 (COVID-19) has been reviewed systematically, prophylactic candidates remain unexplored.

Objectives: To map pre- and postexposure prophylactic (PrEP and PEP) candidate for COVID-19.

Data sources: PubMed/Medline, Embase, International Committee of Medical Journal Editors and International Clinical Trials Registry Platform clinical trial registries and medRxiv.

Study eligibility criteria and participants: All studies in humans or animals and randomized controlled trials (RCTs) in humans reporting primary data on prophylactic candidates against COVID-19, excluding studies focused on key populations.

Interventions: PrEP and PEP candidate for COVID-19.

Methods: Systematic review and qualitative synthesis of COVID-19 PrEP and PEP studies and RCTs complemented by search of medRxiv and PubMed and Embase for studies reporting RCT outcomes since systematic review search completion.

Results: We identified 13 studies (from 2119 database records) and 117 RCTs (from 5565 RCTs listed in the registries) that met the inclusion criteria. Non-RCT studies reported on cross-sectional studies using hydroxychloroquine (HCQ) in humans (n = 2) or reported on animal studies (n = 7), most of which used antibodies. All five completed RCTs focused on the use of HCQ as either PrEP or PEP, and these and the cross-sectional studies reported no prophylactic effect. The majority of ongoing RCTs evaluated HCQ or other existing candidates including non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, anti(retro)virals or use of vitamins and supplements.

Conclusions: The key message from completed studies and RCTs seems to be that HCQ does not work. There is little evidence regarding other compounds, with all RCTs using candidates other than HCQ still ongoing. It remains to be seen if the portfolio of existing molecules being evaluated in RCTs will identify successful prophylaxis against COVID-19 or if there is a need for the development of new candidates.

Keywords: COVID-19; Prophylaxis; Randomized control trials; SARS-CoV-2; Systematic review.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Systematic search flow diagram and search terms. ∗Database search records excluded, as follows: 32 studies did not explore prophylactic candidates or measure outcome; 11 had a clinical trial protocol; nine were narrative reviews, opinion pieces or case reports; one focused on key populations; and for one study we could not find full text. ∗∗Excluded RCT search records.

Similar articles

Cited by

References

    1. Han Y., Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective. J Med Virol. 2020;92:639–644. doi: 10.1002/jmv.25749. - DOI - PMC - PubMed
    1. Vaughan A. 16 September 2020. Coronavirus death toll reaches 1 million – how did we get here? New Scientist.https://www.newscientist.com/article/mg24733003-600-coronavirus-death-to... Available at:
    1. European Data Portal . 30 June 2020. Pressure on healthcare systems: coping with demand for ICU and hospital beds.https://www.europeandataportal.eu/en/impact-studies/covid-19/pressure-he... Available at:
    1. Tanne J.H., Hayasaki E., Zastrow M., Pulla P., Smith P., Rada A.G. COVID-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ. 2020;368 doi: 10.1136/bmj.m1090. - DOI - PubMed
    1. World Bank . 8 June 2020. The global economic outlook during the COVID-19 pandemic: a changed world.https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic... Available at:

Publication types

MeSH terms

Substances

LinkOut - more resources